After 4 weeks of treatment, serum biochemistry showed clear hepatocellular injury in the MTD (IV) group, with AST 223 ± 73.7 U/L vs. 93.0 ± 19.3 U/L and ALT 52.5 ± 11.5 U/L vs. 31.2 ± 7.19 U/L (tumor control), together with moderate renal stress (BUN 26.6 ± 1.90 mg/dL vs. 20.0 ± 2.80 mg/dL; CRE 0.331 ± 0.021 mg/dL vs. 0.287 ± 0.028 mg/dL). The gene discussed is GPT; the disease is neoplasm.